Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Immunological Memory01:23

Immunological Memory

3.2K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
3.2K
Viral Recombination00:57

Viral Recombination

23.7K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Development of Immunocompetence01:22

Development of Immunocompetence

419
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
419
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

297
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound dynamics during treatment of pulmonary and extra-pulmonary TB.

IJTLD open·2026
Same author

[Prevention of infectious diseases : The role of infectious disease specialists].

Innere Medizin (Heidelberg, Germany)·2026
Same author

Caseload, clinical spectrum and economic burden of infectious diseases in patients discharged from hospitals in Germany.

Infection·2025
Same author

Definitions and symptoms of the post-COVID syndrome: an updated systematic umbrella review.

European archives of psychiatry and clinical neuroscience·2024
Same author

Outbreak of Pseudomonas aeruginosa infections after CT-guided spinal injections.

The Journal of hospital infection·2021
Same author

[Development of vaccines for prevention of COVID-19: part 3].

Der Internist·2021
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Optimal blood pressure control in patients with diabetes and arterial hypertension: interpreting the BPROAD study].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Distributive justice in healthcare during times of change: a medical ethics perspective].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Update on the pharmacotherapy of chronic heart failure with reduced ejection fraction: from four to six pillars?]

Innere Medizin (Heidelberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Aug 23, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

[Recurrent SARS-CoV-2 infections in immunodeficiency].

L Tometten1, J J Malin1, E Pracht1

  • 1Klinik I für Innere Medizin, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Innere Medizin (Heidelberg, Germany)
|October 28, 2022
PubMed
Summary
This summary is machine-generated.

Immunocompromised patients with B-cell lymphoma face recurrent SARS-CoV-2 infections. Limited treatment options exist for these chronic viral infections, posing a significant health challenge.

Keywords:
Antiviral treatmentB‑cell neoplasiaCOVID-19ImmunodeficiencyMonoclonal antibodies

More Related Videos

Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques
13:13

Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques

Published on: September 25, 2018

10.7K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Aug 23, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K
Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques
13:13

Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques

Published on: September 25, 2018

10.7K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Area of Science:

  • Immunology
  • Virology
  • Oncology

Context:

  • A patient with B-cell lymphoma and immunodeficiency experienced recurrent SARS-CoV-2 infections.
  • The ongoing SARS-CoV-2 pandemic presents unique challenges for immunocompromised individuals.
  • Limited therapeutic options are available for chronic and recurrent SARS-CoV-2 in this population.

Purpose:

  • To highlight the challenges in managing recurrent SARS-CoV-2 infections in immunocompromised patients.
  • To underscore the need for effective therapeutic strategies against SARS-CoV-2 in patients with B-cell lymphoma.
  • To address the growing threat of immune escape variants in the context of chronic viral infections.

Summary:

  • Recurrent SARS-CoV-2 infections pose a significant threat to patients with B-cell lymphoma and immunodeficiency.
  • The emergence of SARS-CoV-2 variants with immune escape mechanisms further complicates treatment.
  • Managing these chronic infections in immunocompromised individuals presents a substantial clinical challenge.

Impact:

  • This case emphasizes the critical need for novel therapeutic approaches for immunocompromised patients facing persistent SARS-CoV-2 infections.
  • Understanding the management of chronic SARS-CoV-2 in B-cell lymphoma patients is crucial for clinical decision-making.
  • The findings highlight the vulnerability of immunocompromised populations to evolving viral threats and the importance of accessible treatments.